Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole

References

• Lamoureux F, Duflot T, Woillard JB, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016;47(2):124–131. doi:10.1016/j.ijantimicag.2015.12.003
   PubMed Web of Science ®Google Scholar
• Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother. 2007;60(5):1104–1107. doi:10.1093/jac/dkm330
   Web of Science ®Google Scholar
• Gautier-Veyret E, Fonrose X, Tonini J, et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome P450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother. 2015;59(4):2305–2314. doi:10.1128/AAC.04838-14
   Web of Science ®Google Scholar
• Veringa A, ter Avest M, Span LFR, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72(1):261–267. doi:10.1093/jac/dkw349
   PubMed Web of Science ®Google Scholar
• Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–442. doi:10.1016/j.ijantimicag.2014.07.013
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N -oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–547. doi:10.1124/dmd.31.5.540
   PubMed Web of Science ®Google Scholar
• Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–915. doi:10.1111/j.1365-2125.2009.03534.x
   PubMed Web of Science ®Google Scholar
• Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(9):1698–1711. doi:10.1124/dmd.112.045575
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39(11):2020–2033. doi:10.1124/dmd.111.041293
   PubMed Web of Science ®Google Scholar
• Yan M, Wu ZF, Tang D, et al. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother. 2018;108:60–64. doi:10.1016/j.biopha.2018.08.121
   PubMed Web of Science ®Google Scholar
• Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015;59(9):5548–5554. doi:10.1128/AAC.00884-15
   PubMed Web of Science ®Google Scholar
• Ikemura K, Hiramatsu S, Okuda M. Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front Pharmacol. 2017;8:1–5. doi:10.3389/fphar.2017.00911
   Web of Science ®Google Scholar
• De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779–786. doi:10.2217/14796694.1.6.779
   PubMedGoogle Scholar
• Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett. 2015;356(2):697–703. doi:10.1016/j.canlet.2014.10.017
   Web of Science ®Google Scholar
• De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007;67(11):5408–5417. doi:10.1158/0008-5472.CAN-06-4095
   PubMed Web of Science ®Google Scholar
• Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int J Antimicrob Agents. 2017;49(4):403–409. doi:10.1016/j.ijantimicag.2016.11.025
   Web of Science ®Google Scholar
• Hashemizadeh Z, Badiee P, Malekhoseini SA, Raeisi Shahraki H, Geramizadeh B, Montaseri H. Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. Antimicrob Agents Chemother. 2017;61(12):1–10. doi:10.1128/AAC.01211-17
   Web of Science ®Google Scholar
• Pfizer Canada Inc. VFEND (Voriconazole) product monograph; 2016:1–58. Available from: https://www.pfizer.ca/sites/default/files/202102/Vfend_PM_E_243931_01-Feb-2021.pdf (accessed on October 26, 2021).
   Google Scholar
• Wang T, Yan M, Tang D, et al. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child–Pugh class B and C cirrhosis: a multicenter study. Int J Infect Dis. 2018;72:49–54. doi:10.1016/j.ijid.2018.05.009
   PubMed Web of Science ®Google Scholar
• Hassan A, Burhenne J, Riedel KD, et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 2011;33(1):86–93. doi:10.1097/FTD.0b013e31820530cd
   Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223. doi:10.1038/gim.2016.87
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang X, Ke X, Du G, Yang K. Individualized medication of voriconazole: a practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit. 2018;40(6):663–674. doi:10.1097/FTD.0000000000000561
   PubMed Web of Science ®Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi:10.1093/jac/dkw045
   PubMed Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014;209(12):1941–1948. doi:10.1093/infdis/jiu017
   PubMed Web of Science ®Google Scholar
• Miner P, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–2620. doi:10.1016/j.amjgastroenterol.2003.09.053
   PubMed Web of Science ®Google Scholar
• Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60(8):531–539. doi:10.1007/s00228-004-0804-6
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–1311. doi:10.1016/j.jacc.2011.12.024
   PubMed Web of Science ®Google Scholar
• Mafuru M, Wu S, He S, Lu X, Huang J, Jiang H. The influence of proinflammatory cytokines on voriconazole trough concentration in patients with different forms of hematologic disorders. J Clin Pharmacol. 2019;59(10):1340–1350. doi:10.1002/jcph.1422
   PubMed Web of Science ®Google Scholar